– CANADA, Montreal – IBEX Technologies Inc. (TSX-V:IBT) is pleased to announce the appointment of two new directors, following a search by IBEX’s Corporate Governance Committee, chaired by Robert DeLuccia, IBEX’s Lead Director.

Joseph Zimmermann, PhD, currently President, CEO and Founder of Biodextris Inc., Laval, Quebec, has joined the Board to fill the vacancy created by the untimely passing of Bernard Patriacca. Dr. Zimmermann received a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology, a Masters of Philosophy in Pharmacology from Cambridge University (UK) and a Bachelor of Science in Chemical Engineering from Columbia University.

Bruce Connop, PhD, currently Vice President, Non-Clinical & Pharmaceutical Development, Transition Therapeutics, has also joined IBEX’s Board, thereby expanding the Board to six directors, five of whom are independent. Dr. Connop received a doctorate in Pharmacology & Toxicology from Queen’s University, Kingston, Ontario, followed by a Post-Doctoral Fellowship at the University of British Columbia.

“On behalf of the Board, I am extremely pleased to add two such accomplished executives to our Board of Directors”, said Paul Baehr, Chairman and CEO of IBEX.

The appointments of Dr. Joseph Zimmermann and Dr. Bruce Connop to IBEX’s Board of Directors are subject to approval by the TSX Venture Exchange.

ABOUT IBEX

IBEX manufactures and markets proteins for biomedical use through its wholly owned subsidiaries IBEX Pharmaceuticals Inc. (Montreal, QC) and Bio-Research Products, Inc. (North Liberty, IA). IBEX Pharmaceuticals also manufactures and markets a series of arthritis assays which are widely used in osteoarthritis research.

For more information : http://www.ibex.ca

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here the original post =>

Comments are closed.